Remdesivir helped the patients said a study
In Mumbai, the severely l covid-19 patients have been much better after receiving Remdesivir and tocilizumab. Patients who received one of them or the combination of both of them have been much better as compared to those who haven’t received any dosage of Remdesivir and tocilizumab. 
The rate of discharge is 66 % for Remdesivir 80% for tocilizumab and 34% for the patients who received the combination of them. The doctors studied the effect of Remdesivir and tocilizumab on 521 patients of KEM hospital.
Out of 334 patients discharged, only some of them required supplemental oxygen. The doctors noticed that hospitalization was maximum tocilizumab as it was 47 days, 14 days in case of Remdesivir, and 10 days in case of patients who received both.
Dr. Vishal Gupta, associate professor, intensive care, department of medicine, from the hospital and also the principal investigator of the study explained that Patients needing vasopressors, medicines that enable tightening blood vessels and boosting blood pressure, had greater mortality.
Dr. Sushrut Ingawale, a third-year resident, who worked on the study with Dr. Amit Bhondve, Dr. Wasim Khot, and nine others explained that The study examined that patients below 55 years are around three times more likely to receive a discharge. The chances of patients with face masks or nasal prongs surviving are 34 times more than the ones on invasive ventilation
However, most of these factors were different for the group that got tocilizumab. “It was observed that tocilizumab if provided at a suitable time to the right patients, helped in improved survival and less need for mechanical ventilation. In old and unstable patients, it did not seem to have an identical outcome. For example, the drug may not improve effects for patients who already have a secondary infection,” told Gupta.
The study states that these drugs can provide better clinical effects, but a bigger multi-centric trial is needed.
As a tertiary care hospital, KEM mostly got critical patients. The researchers categorized the 521 patients in three randomized treatment groups based on the factors like availability and supply of the two drugs between June 1 and September 30, 2020, and when compared it with a fourth group, admitted to the ICU when these drugs were not available. More than half the patients were above 55, male (62%), with diabetes (41.8%) and hypertension (42.4%) as the most common comorbidities.
